Misoprostol
Brand name: Cytotec
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Prevention of NSAID-induced gastric ulcers in patients at high risk of complications | Adults at high risk (elderly, history of ulcer, concomitant debilitating disease) | Co-therapy with NSAIDs | FDA Approved |
Misoprostol is FDA-approved solely for reducing the risk of NSAID-induced gastric ulcers in high-risk patients. In pivotal 12-week trials, misoprostol 200 mcg QID reduced gastric ulcer incidence from approximately 22% (placebo) to 2% in patients taking ibuprofen, piroxicam, or naproxen. The drug has not been shown to reduce duodenal ulcer risk, nor does it relieve NSAID-associated gastrointestinal pain or discomfort.
Cervical ripening and labor induction (term pregnancy) — Evidence quality: High. Extensively studied; WHO and ACOG support 25 mcg PV or PO. Hospital setting required. Contraindicated with prior cesarean section.
Medical termination of pregnancy (with mifepristone) — Evidence quality: High. WHO/FIGO-endorsed regimen: mifepristone 200 mg PO followed by misoprostol 800 mcg buccally 24–48 hours later.
Early pregnancy loss management — Evidence quality: High. ACOG recommends 800 mcg vaginally, with repeat dosing as needed (Practice Bulletin No. 200).
Postpartum hemorrhage — prevention — Evidence quality: High. FIGO/WHO recommend 600 mcg PO or sublingual immediately after delivery where oxytocin is unavailable.
Postpartum hemorrhage — treatment — Evidence quality: High. FIGO endorses 800 mcg sublingually when IV oxytocin is unavailable or insufficient.
Incomplete abortion — Evidence quality: Moderate. FIGO 2023: 400–600 mcg SL or PO as a single dose.
Cervical preparation before surgical procedures — Evidence quality: Moderate. 400 mcg PV or SL 3–4 hours before procedure.
Dosing
FDA-Approved Gastric Ulcer Prevention
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| NSAID-induced gastric ulcer prevention — standard risk | 200 mcg QID with food | 200 mcg QID | 800 mcg/day | Take with meals; last dose at bedtime Continue for duration of NSAID therapy |
| NSAID-induced gastric ulcer prevention — dose-limited by tolerability | 100 mcg QID with food | 100 mcg QID | 400 mcg/day | Use if 200 mcg dose not tolerated (diarrhea) Less effective than 200 mcg in clinical trials |
Off-Label Obstetric and Gynecologic Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Cervical ripening / labor induction (term, live fetus) | 25 mcg PV or PO | 25 mcg q3–6h (PV) or q2h (PO) | Titrate to contractions | Hospital setting only; CTG monitoring required Contraindicated with prior cesarean; avoid SL/buccal for this indication (ACOG) |
| Medical abortion (≤10 weeks, with mifepristone) | 800 mcg buccally | Single dose, 24–48 h after mifepristone 200 mg PO | 800 mcg | Hold tablets in cheeks for 30 min, swallow remainder Per FDA-approved Mifeprex REMS regimen |
| Early pregnancy loss (<13 weeks) | 800 mcg PV | Repeat 800 mcg if needed after 3 h (within 7 days) | 1600 mcg total | Pre-treatment with mifepristone 200 mg improves efficacy ACOG Practice Bulletin No. 200 |
| PPH prevention (where oxytocin unavailable) | 600 mcg PO or SL × 1 | Single dose immediately after delivery | 600 mcg | Confirm no additional fetus in utero before administration WHO/FIGO recommendation for low-resource settings |
| PPH treatment (uterine atony, refractory to oxytocin) | 800 mcg SL × 1 | Single dose | 800 mcg | May cause significant shivering and fever ≥38°C FIGO 2012/2023 guideline; ACOG PPH bundle |
| Incomplete abortion | 400–600 mcg SL or PO × 1 | Single dose | 600 mcg | Alternatives: 800 mcg PV or buccal FIGO 2023 dosing chart |
| Cervical preparation before surgical procedures (<13 weeks) | 400 mcg PV or SL | Single dose, 3–4 h pre-procedure | 400 mcg | Osmotic dilators preferred for later gestations FIGO 2023; consider in adolescents or stenotic cervix |
Special Population Adjustments
| Population | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Renal impairment | 200 mcg QID | 100–200 mcg QID | 800 mcg/day | T½ and AUC approximately doubled; reduce dose if not tolerated No routine adjustment needed (FDA PI) |
| Elderly (≥65 years) | 200 mcg QID | 200 mcg QID | 800 mcg/day | AUC increased in elderly; no safety differences seen in ~500 patients ≥65 years Reduce if GI side effects problematic |
| Pediatric | Safety and efficacy not established | Not FDA-approved for pediatric use | ||
For the GI indication, misoprostol should always be taken with meals and the last dose at bedtime. Taking the drug with food reduces the incidence and severity of diarrhea. In contrast, for obstetric indications, the route and timing vary significantly: sublingual and buccal routes provide faster peak levels and are preferred for acute situations like PPH treatment, while vaginal administration provides more sustained uterine activity for labor induction.
Pharmacology
Mechanism of Action
Misoprostol is a synthetic prostaglandin E1 analog that acts through two clinically distinct mechanisms. In the gastrointestinal tract, it binds to prostaglandin E receptors on gastric parietal cells, inhibiting basal and stimulated gastric acid secretion. This antisecretory effect is apparent within 30 minutes of oral dosing and lasts at least 3 hours. Simultaneously, misoprostol enhances mucosal defense by stimulating bicarbonate and mucus production, replacing the protective prostaglandins depleted by NSAID-mediated cyclooxygenase inhibition. In the uterus, misoprostol binds to myometrial prostaglandin receptors, causing cervical softening (ripening) through collagen degradation and increased water content, as well as coordinated myometrial contractions. These uterotonic effects are dose-dependent and form the basis for its extensive obstetric applications. The drug also moderately reduces pepsin concentration under basal conditions and has no clinically significant effects on gastrin, prolactin, thyroid-stimulating hormone, or other hormonal systems at recommended doses.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Extensive oral absorption; Tmax 12 ± 3 min (fasting); Cmax reduced by food and antacids | Rapid onset for GI protection; food reduces peak levels but clinical efficacy maintained (trials used with food) |
| Distribution | Protein binding <90%, concentration-independent; Vd not well characterized | Distributes to gastric mucosa and myometrium; excreted in breast milk (peak ~1 h post-dose, <1 pg/mL by 5 h) |
| Metabolism | Rapid de-esterification to misoprostol acid (active); further β-oxidation and ω-oxidation to PGF analogs | Metabolized like a fatty acid; no CYP-mediated interactions; no dose adjustment for hepatic impairment |
| Elimination | ~80% excreted in urine; t½ 20–40 min; no accumulation with multiple dosing | Approximately doubled t½ and AUC in renal impairment; unlikely dialyzable |
Side Effects
The adverse effect profile of misoprostol differs markedly between its GI and obstetric uses. The data below primarily reflect the GI indication (clinical trials of over 5,000 patients at 400–800 mcg daily). Obstetric-specific adverse effects are addressed separately.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhea | 13% (average); 14–40% at 800 mcg | Dose-related; onset typically within 13 days; usually self-limiting by day 8; take with food to minimize; avoid magnesium-containing antacids |
| Abdominal pain | 7–20% | Reported in 13–20% in NSAID trials; ~7% across all studies; no consistent difference from placebo in controlled trials |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 3.2% | Usually mild and transient |
| Flatulence | 2.9% | Gastrointestinal prostaglandin effect; no significant difference from placebo |
| Headache | 2.4% | No consistent difference from placebo |
| Dyspepsia | 2.0% | Not significantly different from placebo |
| Vomiting | 1.3% | More prominent with obstetric doses |
| Constipation | 1.1% | Not significantly different from placebo |
In women receiving misoprostol for GI protection, gynecologic events were reported: spotting (0.7%), cramps (0.6%), hypermenorrhea (0.5%), menstrual disorder (0.3%), and dysmenorrhea (0.1%). Postmenopausal vaginal bleeding has also been reported and requires investigation to rule out gynecologic pathology.
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Uterine rupture (obstetric use) | Rare (higher with prior cesarean) | During labor induction or abortion | Immediate laparotomy; may require hysterectomy; contraindicated with prior uterine scar at ≥28 weeks |
| Uterine tachysystole / tetany (obstetric use) | Uncommon; dose-dependent | Within hours of administration | Stop misoprostol; consider tocolytic (terbutaline); continuous fetal monitoring; urgent delivery if fetal distress |
| Severe dehydration from profound diarrhea (GI use) | Rare | First 1–2 weeks | IV fluid resuscitation; discontinue misoprostol; high risk in elderly or IBD patients |
| Teratogenicity (if pregnancy continues after exposure) | Reported in failed abortions | First trimester exposure | Skull defects, cranial nerve palsies, facial malformations, limb defects reported; pregnancy testing required before GI use |
| High fever >40°C with autonomic dysfunction (obstetric PPH doses) | Uncommon at treatment doses | Within hours of high-dose administration | Transient; supportive care; may include tachycardia, agitation, disorientation, convulsions |
| Anaphylactic reaction | Very rare | Any time | Emergency treatment; permanent discontinuation |
Diarrhea is the most clinically relevant GI adverse effect. It is dose-dependent (much more common at 800 mcg/day than 400 mcg/day), usually develops within the first two weeks of therapy, and typically resolves spontaneously within about 8 days. Administering the drug with food, avoiding magnesium-containing antacids, and starting at 100 mcg QID if the patient has a history of diarrhea-predominant conditions can reduce the incidence. Patients with inflammatory bowel disease or conditions predisposing to dehydration should be monitored with particular care.
Drug Interactions
Misoprostol has a remarkably limited systemic drug interaction profile. It is metabolized like a fatty acid rather than through CYP pathways. Studies have confirmed no clinically significant pharmacokinetic interactions with ibuprofen, diclofenac, aspirin, antipyrine, propranolol, or diazepam. The principal interactions are pharmacodynamic rather than pharmacokinetic.
Monitoring
-
Pregnancy Test
Before initiation (GI indication)
Routine Negative serum pregnancy test required within 2 weeks before starting misoprostol for NSAID gastroprotection in women of childbearing potential. Therapy should begin on day 2 or 3 of the menstrual cycle. -
GI Symptoms
First 2 weeks; then as needed
Routine Monitor for diarrhea and abdominal pain. Most GI effects emerge within the first 13 days and resolve by day 8. Reduce dose to 100 mcg QID if intolerable. Patients with IBD or dehydration risk need close monitoring. -
Uterine Activity (obstetric use)
Continuous during labor induction
Routine Continuous electronic fetal heart rate and contraction monitoring (CTG) mandatory when misoprostol is used for cervical ripening or labor induction. Hospital setting with access to emergency cesarean is required. -
Vital Signs (obstetric PPH doses)
First 2–4 hours post-dose
Trigger-based High-dose misoprostol (600–800 mcg) for PPH can cause transient fever >40°C, shivering, tachycardia, and rarely, agitation or convulsions. Supportive care as needed; effects are self-limiting. -
Vaginal Bleeding
As clinically indicated
Trigger-based Any vaginal bleeding in postmenopausal women using misoprostol for GI protection warrants diagnostic workup to exclude gynecologic pathology. In obstetric use, monitor blood loss with quantitative or visual estimation. -
Contraception
Ongoing throughout GI therapy
Routine Women of childbearing potential must use effective contraception while taking misoprostol for GI indication and for at least 1 month (or one menstrual cycle) after discontinuation.
Contraindications & Cautions
Absolute Contraindications
- Pregnancy (for GI indication) — misoprostol is an abortifacient and can cause birth defects, premature labor, and uterine rupture. It must not be used for gastroprotection in pregnant women.
- Known allergy to prostaglandins — hypersensitivity to misoprostol or any prostaglandin analog; anaphylactic reactions have been reported.
Relative Contraindications (Specialist Input Recommended)
- Prior cesarean section or major uterine surgery (obstetric use ≥28 weeks) — significantly increased risk of uterine rupture. FIGO states misoprostol is safe below 28 weeks even with prior cesarean scar, but is not recommended at ≥28 weeks in scarred uteri.
- Grand multiparity (obstetric use) — appears to be a risk factor for uterine rupture during labor induction.
- Cephalopelvic disproportion or malpresentation (obstetric use) — uterotonic stimulation is inappropriate when operative delivery is indicated.
Use with Caution
- Inflammatory bowel disease — diarrhea from misoprostol may exacerbate IBD symptoms and precipitate dehydration
- Pre-existing cardiovascular disease — caution advised (FDA PI); safety data in this population are limited
- Women of childbearing potential (GI indication) — requires negative pregnancy test, effective contraception, counseling on abortifacient risk, and initiation on day 2–3 of menses
- Renal impairment — AUC approximately doubled; may need dose reduction if adverse effects occur
- Elderly — AUC increased; no safety differences observed in ~500 patients ≥65 years, but monitor for dehydration from diarrhea
Misoprostol administration to pregnant women can cause birth defects, abortion (sometimes incomplete), premature birth, or uterine rupture. Uterine rupture has been reported when misoprostol was used to induce labor or abortion. The risk of uterine rupture increases with advancing gestational age and with prior uterine surgery, including cesarean delivery. Misoprostol must not be taken by pregnant women to reduce the risk of NSAID-induced ulcers. Patients must be advised of its abortifacient property and warned not to give the drug to others.
Patient Counselling
Purpose of Therapy
When prescribed for stomach protection, misoprostol works by replacing natural protective substances (prostaglandins) that are reduced by your arthritis or pain medication. This helps prevent stomach ulcers that can develop as a side effect of anti-inflammatory drugs. It is essential that you understand this medication can cause a miscarriage or serious harm to an unborn baby if you are or become pregnant.
How to Take
Take misoprostol with each meal and at bedtime as directed by your doctor. Swallow the tablets whole with water. Taking the drug with food helps reduce the chance of diarrhea. Do not give your misoprostol tablets to anyone else, as the medication could be dangerous if that person were pregnant.
Sources
- Cytotec (misoprostol) Tablets — FDA-Approved Prescribing Information, revised February 2018. Pfizer Inc. FDA Label Current FDA-approved prescribing information for Cytotec; source for approved indication, dosing, black box warning, adverse reactions, and pharmacokinetic data.
- Mifeprex (mifepristone) — FDA-Approved Prescribing Information, revised 2019. Danco Laboratories. FDA Label FDA label for the mifepristone-misoprostol regimen; includes misoprostol 800 mcg buccal dosing for medical abortion.
- Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1995;123(4):241–249. PubMed: 7611589 MUCOSA trial demonstrating 40% reduction in serious GI complications with misoprostol in high-risk NSAID users.
- Gallos ID, Papadopoulou A, Man R, et al. Uterotonic agents for preventing postpartum haemorrhage: a network meta-analysis. Cochrane Database Syst Rev. 2018;12:CD011689. PubMed: 30569545 Cochrane network meta-analysis comparing uterotonics for PPH prevention; positions misoprostol relative to oxytocin and other agents.
- Hofmeyr GJ, Gulmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev. 2010;(10):CD000941. PubMed: 20927722 Comprehensive Cochrane review of vaginal misoprostol for labor induction establishing dose-response relationship and safety parameters.
- Morris JL, Winikoff B, Dabash R, et al. FIGO’s updated recommendations for misoprostol used alone in gynecology and obstetrics. Int J Gynaecol Obstet. 2017;138(3):363–366. PubMed: 28643396 FIGO consensus guideline for misoprostol-only regimens across obstetric and gynecologic indications.
- FIGO Committee on Safe Abortion. Mifepristone & Misoprostol Dosing Charts 2023. FIGO 2023 Updated 2023 FIGO dosing charts for misoprostol across all gestational ages and indications including PPH, abortion, and labor induction.
- ACOG Practice Bulletin No. 200: Early Pregnancy Loss. Obstet Gynecol. 2018;132(5):e197–e207. PubMed: 30157093 ACOG guideline recommending misoprostol 800 mcg vaginally for medical management of early pregnancy loss.
- ACOG Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017;130(4):e168–e186. PubMed: 28937571 ACOG guideline including misoprostol in the PPH management bundle for uterine atony.
- WHO Abortion Care Guideline. World Health Organization; Geneva: 2022. PubMed: 35344310 WHO comprehensive guideline on medical and surgical abortion including misoprostol regimens and routes of administration.
- Collins PW. Misoprostol: discovery, development, and clinical applications. Med Res Rev. 1990;10(2):149–172. PubMed: 2109814 Comprehensive review by the Searle chemist who developed misoprostol; covers structure-activity relationships, antisecretory pharmacology, and mucosal protective mechanisms.
- Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(Suppl 2):S160–S167. PubMed: 17963768 Detailed pharmacokinetic comparison across oral, vaginal, sublingual, buccal, and rectal routes; informs route selection for different clinical scenarios.
- Turner JV, Agatonovic-Kustrin S, Ward H. Off-label use of misoprostol in gynaecology. Facts Views Vis Obgyn. 2015;7(4):261–264. PubMed: 27729972 Review summarizing the evidence base for misoprostol’s off-label gynecologic uses and route-specific bioavailability data.
- Zieman M, Fong SK, Benowitz NL, et al. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997;90(1):88–92. PubMed: 9207820 Landmark PK study establishing higher peak levels with oral but more sustained exposure with vaginal misoprostol, guiding route selection for obstetric indications.